Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2025)

C4 Therapeutics' Change in Account Payables history spans 7 years, with the latest figure at -$472000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 168.18% year-over-year to -$472000.0; the TTM value through Dec 2025 reached -$468000.0, down 293.28%, while the annual FY2025 figure was -$468000.0, 293.28% down from the prior year.
  • Change in Account Payables reached -$472000.0 in Q4 2025 per CCCC's latest filing, up from -$885000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q2 2025 to a low of -$2.0 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$241300.0, with a median of -$324000.0 recorded in 2024.
  • The largest YoY upside for Change in Account Payables was 314.55% in 2025 against a maximum downside of 454.4% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $760000.0 in 2021, then plummeted by 241.58% to -$1.1 million in 2022, then soared by 115.71% to $169000.0 in 2023, then plummeted by 204.14% to -$176000.0 in 2024, then tumbled by 168.18% to -$472000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Change in Account Payables are -$472000.0 (Q4 2025), -$885000.0 (Q3 2025), and $1.5 million (Q2 2025).